by European Brain Council (EBC)
On the occasion of the Brain Awareness Week, the European Brain Council (EBC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) launched the RETHINKING Alzheimer’s disease White Paper, calling for change in the detection and diagnosis of Alzheimer’s disease.
Alzheimer’s disease (AD), the most common form of dementia, is a progressive and debilitating neurodegenerative condition which robs people of their memory, their independence, their relationships and, ultimately, their lives. It affects close to 7 million people in the European Union (EU) alone. AD is a growing public health issue with a huge burden for European economies, national healthcare and social care systems and a concern for the future.
The policy recommendations gathered in this White Paper provide solid directions on how to rethink the detection and diagnosis of AD to help overcome the current challenges and be prepared to embrace innovation.
Read more here.